As cancer treatment options expand beyond traditional small-molecule drugs, developers may be able to revisit biological targets once considered difficult or impossible to treat. Cell and gene therapies, RNA-based treatments, targeted protein degradation and antibody-drug conjugates are among the approaches broadening the therapeutic toolkit, according to sponsored content published by GEN - Genetic Engineering and Biotechnology News.
The article says this shift could prompt researchers to examine genomic alterations that received less attention when fewer treatment strategies were available. Cancer-associated variants remain diverse and are not fully understood, including in well-studied forms of the disease. Investigating a wider range of alterations could support biomarker research and therapeutic discovery, both in cancers already served by targeted treatments and in underexplored types with significant unmet need.
Genomic information is used to help identify and prioritize drug targets, as well as to select patients for precision therapies. The article argues that researchers need a comprehensive, reliable and timely view of genomic variation throughout development, from target discovery to patient selection. It adds that multiomics can provide useful context but does not replace broader, deeper examination of genomic changes.
Scaling this work requires infrastructure that can process samples consistently across large cohorts and long studies. Comprehensive genomic profiling can assess changes including single-nucleotide variants, insertions and deletions, copy-number variants and selected gene fusions, helping researchers look beyond familiar markers.
The sponsored article also describes Sampled as an integrated analytical laboratory and biorepository offering sample collection kits, storage, processing, genomic profiling and data analysis for oncology research.